Agile Therapeutics, Inc.
Agile Therapeutics, Inc. AGRX Peers
See (AGRX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AGRX | $1.51 | +3.42% | 10.43M | -0.89 | -$1.70 | N/A |
| ZTS | $154.93 | -3.42% | 68.98B | 27.82 | $5.57 | +1.20% |
| HLN | $10.41 | -0.38% | 48.19B | 24.79 | $0.42 | +1.61% |
| TAK | $13.71 | -0.11% | 43.59B | 59.59 | $0.23 | +4.30% |
| TEVA | $16.89 | -3.40% | 19.35B | -14.68 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14.05B | -180.64 | -$0.73 | N/A |
| RDY | $14.15 | +0.32% | 11.78B | 17.68 | $0.80 | +0.68% |
| NBIX | $118.78 | +1.63% | 11.76B | 40.26 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.52B | -27.84 | -$2.28 | N/A |
| VTRS | $8.42 | -4.21% | 9.88B | -2.65 | -$3.18 | +5.67% |
Stock Comparison
AGRX vs ZTS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ZTS has a market cap of 68.98B. Regarding current trading prices, AGRX is priced at $1.51, while ZTS trades at $154.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZTS's P/E ratio is 27.82. In terms of profitability, AGRX's ROE is +1.04%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, AGRX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs HLN Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, HLN has a market cap of 48.19B. Regarding current trading prices, AGRX is priced at $1.51, while HLN trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HLN's P/E ratio is 24.79. In terms of profitability, AGRX's ROE is +1.04%, compared to HLN's ROE of +0.09%. Regarding short-term risk, AGRX is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs TAK Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TAK has a market cap of 43.59B. Regarding current trading prices, AGRX is priced at $1.51, while TAK trades at $13.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TAK's P/E ratio is 59.59. In terms of profitability, AGRX's ROE is +1.04%, compared to TAK's ROE of +0.04%. Regarding short-term risk, AGRX is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs TEVA Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TEVA has a market cap of 19.35B. Regarding current trading prices, AGRX is priced at $1.51, while TEVA trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TEVA's P/E ratio is -14.68. In terms of profitability, AGRX's ROE is +1.04%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, AGRX is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs ITCI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ITCI has a market cap of 14.05B. Regarding current trading prices, AGRX is priced at $1.51, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AGRX's ROE is +1.04%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs RDY Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, RDY has a market cap of 11.78B. Regarding current trading prices, AGRX is priced at $1.51, while RDY trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RDY's P/E ratio is 17.68. In terms of profitability, AGRX's ROE is +1.04%, compared to RDY's ROE of +0.18%. Regarding short-term risk, AGRX is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs NBIX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, NBIX has a market cap of 11.76B. Regarding current trading prices, AGRX is priced at $1.51, while NBIX trades at $118.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas NBIX's P/E ratio is 40.26. In terms of profitability, AGRX's ROE is +1.04%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, AGRX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs CTLT Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CTLT has a market cap of 11.52B. Regarding current trading prices, AGRX is priced at $1.51, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AGRX's ROE is +1.04%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, AGRX is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs VTRS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, VTRS has a market cap of 9.88B. Regarding current trading prices, AGRX is priced at $1.51, while VTRS trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas VTRS's P/E ratio is -2.65. In terms of profitability, AGRX's ROE is +1.04%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, AGRX is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ELAN Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ELAN has a market cap of 6.39B. Regarding current trading prices, AGRX is priced at $1.51, while ELAN trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ELAN's P/E ratio is 16.93. In terms of profitability, AGRX's ROE is +1.04%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs LNTH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, LNTH has a market cap of 5.45B. Regarding current trading prices, AGRX is priced at $1.51, while LNTH trades at $78.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LNTH's P/E ratio is 22.45. In terms of profitability, AGRX's ROE is +1.04%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AGRX is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs RGC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, RGC has a market cap of 4.46B. Regarding current trading prices, AGRX is priced at $1.51, while RGC trades at $342.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RGC's P/E ratio is -1039.36. In terms of profitability, AGRX's ROE is +1.04%, compared to RGC's ROE of -0.25%. Regarding short-term risk, AGRX is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs PRGO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PRGO has a market cap of 3.58B. Regarding current trading prices, AGRX is priced at $1.51, while PRGO trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PRGO's P/E ratio is -21.67. In terms of profitability, AGRX's ROE is +1.04%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, AGRX is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs AMRX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, AMRX has a market cap of 3.42B. Regarding current trading prices, AGRX is priced at $1.51, while AMRX trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AMRX's P/E ratio is -183.50. In terms of profitability, AGRX's ROE is +1.04%, compared to AMRX's ROE of -0.00%. Regarding short-term risk, AGRX is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ALVO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ALVO has a market cap of 3.17B. Regarding current trading prices, AGRX is priced at $1.51, while ALVO trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALVO's P/E ratio is 27.63. In terms of profitability, AGRX's ROE is +1.04%, compared to ALVO's ROE of +0.46%. Regarding short-term risk, AGRX is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ALVOW Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ALVOW has a market cap of 3.06B. Regarding current trading prices, AGRX is priced at $1.51, while ALVOW trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALVOW's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +1.04%, compared to ALVOW's ROE of +0.46%. Regarding short-term risk, AGRX is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs EVO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EVO has a market cap of 2.90B. Regarding current trading prices, AGRX is priced at $1.51, while EVO trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EVO's P/E ratio is -6.18. In terms of profitability, AGRX's ROE is +1.04%, compared to EVO's ROE of -0.19%. Regarding short-term risk, AGRX is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs HCM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, HCM has a market cap of 2.46B. Regarding current trading prices, AGRX is priced at $1.51, while HCM trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HCM's P/E ratio is 66.50. In terms of profitability, AGRX's ROE is +1.04%, compared to HCM's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs DCPH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, DCPH has a market cap of 2.21B. Regarding current trading prices, AGRX is priced at $1.51, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AGRX's ROE is +1.04%, compared to DCPH's ROE of -0.52%. Regarding short-term risk, AGRX is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs EMBCV Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EMBCV has a market cap of 1.91B. Regarding current trading prices, AGRX is priced at $1.51, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +1.04%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, AGRX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs SUPN Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SUPN has a market cap of 1.77B. Regarding current trading prices, AGRX is priced at $1.51, while SUPN trades at $31.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SUPN's P/E ratio is 28.41. In terms of profitability, AGRX's ROE is +1.04%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs BHC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BHC has a market cap of 1.69B. Regarding current trading prices, AGRX is priced at $1.51, while BHC trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BHC's P/E ratio is -38.00. In terms of profitability, AGRX's ROE is +1.04%, compared to BHC's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs BGM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BGM has a market cap of 1.68B. Regarding current trading prices, AGRX is priced at $1.51, while BGM trades at $11.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BGM's P/E ratio is -57.75. In terms of profitability, AGRX's ROE is +1.04%, compared to BGM's ROE of N/A. Regarding short-term risk, AGRX is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs TARO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TARO has a market cap of 1.62B. Regarding current trading prices, AGRX is priced at $1.51, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, AGRX's ROE is +1.04%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AGRX is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs INDV Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, INDV has a market cap of 1.38B. Regarding current trading prices, AGRX is priced at $1.51, while INDV trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas INDV's P/E ratio is -220.60. In terms of profitability, AGRX's ROE is +1.04%, compared to INDV's ROE of -0.01%. Regarding short-term risk, AGRX is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ANIP Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ANIP has a market cap of 1.31B. Regarding current trading prices, AGRX is priced at $1.51, while ANIP trades at $60.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ANIP's P/E ratio is -51.16. In terms of profitability, AGRX's ROE is +1.04%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, AGRX is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs PCRX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PCRX has a market cap of 1.13B. Regarding current trading prices, AGRX is priced at $1.51, while PCRX trades at $24.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PCRX's P/E ratio is -10.92. In terms of profitability, AGRX's ROE is +1.04%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, AGRX is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs DVAX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, DVAX has a market cap of 1.13B. Regarding current trading prices, AGRX is priced at $1.51, while DVAX trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DVAX's P/E ratio is -18.80. In terms of profitability, AGRX's ROE is +1.04%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AGRX is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs AMPH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, AMPH has a market cap of 1.10B. Regarding current trading prices, AGRX is priced at $1.51, while AMPH trades at $23.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AMPH's P/E ratio is 8.44. In terms of profitability, AGRX's ROE is +1.04%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, AGRX is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs PAHC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PAHC has a market cap of 946.87M. Regarding current trading prices, AGRX is priced at $1.51, while PAHC trades at $23.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PAHC's P/E ratio is 29.95. In terms of profitability, AGRX's ROE is +1.04%, compared to PAHC's ROE of +0.07%. Regarding short-term risk, AGRX is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs COLL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, COLL has a market cap of 933.09M. Regarding current trading prices, AGRX is priced at $1.51, while COLL trades at $29.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas COLL's P/E ratio is 23.60. In terms of profitability, AGRX's ROE is +1.04%, compared to COLL's ROE of +0.19%. Regarding short-term risk, AGRX is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs HROW Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, HROW has a market cap of 922.08M. Regarding current trading prices, AGRX is priced at $1.51, while HROW trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HROW's P/E ratio is -41.19. In terms of profitability, AGRX's ROE is +1.04%, compared to HROW's ROE of -0.36%. Regarding short-term risk, AGRX is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs PETQ Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PETQ has a market cap of 919.17M. Regarding current trading prices, AGRX is priced at $1.51, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AGRX's ROE is +1.04%, compared to PETQ's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs AVDL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, AVDL has a market cap of 825.18M. Regarding current trading prices, AGRX is priced at $1.51, while AVDL trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AVDL's P/E ratio is -32.81. In terms of profitability, AGRX's ROE is +1.04%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, AGRX is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs CRON Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CRON has a market cap of 793.96M. Regarding current trading prices, AGRX is priced at $1.51, while CRON trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CRON's P/E ratio is 14.71. In terms of profitability, AGRX's ROE is +1.04%, compared to CRON's ROE of +0.04%. Regarding short-term risk, AGRX is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs EMBC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EMBC has a market cap of 677.35M. Regarding current trading prices, AGRX is priced at $1.51, while EMBC trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EMBC's P/E ratio is 13.02. In terms of profitability, AGRX's ROE is +1.04%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, AGRX is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs EOLS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EOLS has a market cap of 644.11M. Regarding current trading prices, AGRX is priced at $1.51, while EOLS trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EOLS's P/E ratio is -11.22. In terms of profitability, AGRX's ROE is +1.04%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, AGRX is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs BDSI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BDSI has a market cap of 577.05M. Regarding current trading prices, AGRX is priced at $1.51, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AGRX's ROE is +1.04%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AGRX is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs TLRY Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TLRY has a market cap of 445.45M. Regarding current trading prices, AGRX is priced at $1.51, while TLRY trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TLRY's P/E ratio is -0.40. In terms of profitability, AGRX's ROE is +1.04%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, AGRX is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs KMDA Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, KMDA has a market cap of 405.41M. Regarding current trading prices, AGRX is priced at $1.51, while KMDA trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas KMDA's P/E ratio is 28.20. In terms of profitability, AGRX's ROE is +1.04%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, AGRX is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs ZYBT Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ZYBT has a market cap of 399.98M. Regarding current trading prices, AGRX is priced at $1.51, while ZYBT trades at $8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZYBT's P/E ratio is 140.67. In terms of profitability, AGRX's ROE is +1.04%, compared to ZYBT's ROE of N/A. Regarding short-term risk, AGRX is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs SIGA Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SIGA has a market cap of 390.58M. Regarding current trading prices, AGRX is priced at $1.51, while SIGA trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SIGA's P/E ratio is 4.56. In terms of profitability, AGRX's ROE is +1.04%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, AGRX is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ORGO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ORGO has a market cap of 381.83M. Regarding current trading prices, AGRX is priced at $1.51, while ORGO trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ORGO's P/E ratio is -17.71. In terms of profitability, AGRX's ROE is +1.04%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, AGRX is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs TKNO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TKNO has a market cap of 348.43M. Regarding current trading prices, AGRX is priced at $1.51, while TKNO trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TKNO's P/E ratio is -14.17. In terms of profitability, AGRX's ROE is +1.04%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, AGRX is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs SNDL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SNDL has a market cap of 329.34M. Regarding current trading prices, AGRX is priced at $1.51, while SNDL trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SNDL's P/E ratio is -4.41. In terms of profitability, AGRX's ROE is +1.04%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, AGRX is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs EBS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EBS has a market cap of 305.58M. Regarding current trading prices, AGRX is priced at $1.51, while EBS trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EBS's P/E ratio is -2.18. In terms of profitability, AGRX's ROE is +1.04%, compared to EBS's ROE of -0.27%. Regarding short-term risk, AGRX is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs ALIM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ALIM has a market cap of 301.29M. Regarding current trading prices, AGRX is priced at $1.51, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AGRX's ROE is +1.04%, compared to ALIM's ROE of -0.34%. Regarding short-term risk, AGRX is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ACB Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ACB has a market cap of 276.62M. Regarding current trading prices, AGRX is priced at $1.51, while ACB trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ACB's P/E ratio is 26.53. In terms of profitability, AGRX's ROE is +1.04%, compared to ACB's ROE of -0.06%. Regarding short-term risk, AGRX is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs LNDC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, LNDC has a market cap of 263.63M. Regarding current trading prices, AGRX is priced at $1.51, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AGRX's ROE is +1.04%, compared to LNDC's ROE of -0.65%. Regarding short-term risk, AGRX is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs CGC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CGC has a market cap of 253.93M. Regarding current trading prices, AGRX is priced at $1.51, while CGC trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CGC's P/E ratio is -0.38. In terms of profitability, AGRX's ROE is +1.04%, compared to CGC's ROE of -0.88%. Regarding short-term risk, AGRX is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs LFCR Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, LFCR has a market cap of 246.96M. Regarding current trading prices, AGRX is priced at $1.51, while LFCR trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LFCR's P/E ratio is -4.54. In terms of profitability, AGRX's ROE is +1.04%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, AGRX is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs TYHT Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TYHT has a market cap of 229.17M. Regarding current trading prices, AGRX is priced at $1.51, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AGRX's ROE is +1.04%, compared to TYHT's ROE of -0.84%. Regarding short-term risk, AGRX is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs AQST Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, AQST has a market cap of 220.51M. Regarding current trading prices, AGRX is priced at $1.51, while AQST trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AQST's P/E ratio is -4.35. In terms of profitability, AGRX's ROE is +1.04%, compared to AQST's ROE of +1.07%. Regarding short-term risk, AGRX is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs REPH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, REPH has a market cap of 177.42M. Regarding current trading prices, AGRX is priced at $1.51, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, AGRX's ROE is +1.04%, compared to REPH's ROE of -0.15%. Regarding short-term risk, AGRX is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs OGI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, OGI has a market cap of 154.03M. Regarding current trading prices, AGRX is priced at $1.51, while OGI trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas OGI's P/E ratio is -3.49. In terms of profitability, AGRX's ROE is +1.04%, compared to OGI's ROE of -0.18%. Regarding short-term risk, AGRX is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ESPR Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ESPR has a market cap of 144.69M. Regarding current trading prices, AGRX is priced at $1.51, while ESPR trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ESPR's P/E ratio is -0.86. In terms of profitability, AGRX's ROE is +1.04%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, AGRX is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs DERM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, DERM has a market cap of 138.03M. Regarding current trading prices, AGRX is priced at $1.51, while DERM trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DERM's P/E ratio is -8.29. In terms of profitability, AGRX's ROE is +1.04%, compared to DERM's ROE of -1.06%. Regarding short-term risk, AGRX is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs BIOA Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BIOA has a market cap of 134.80M. Regarding current trading prices, AGRX is priced at $1.51, while BIOA trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BIOA's P/E ratio is -0.57. In terms of profitability, AGRX's ROE is +1.04%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, AGRX is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs THTX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, THTX has a market cap of 116.33M. Regarding current trading prices, AGRX is priced at $1.51, while THTX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas THTX's P/E ratio is -36.14. In terms of profitability, AGRX's ROE is +1.04%, compared to THTX's ROE of +0.16%. Regarding short-term risk, AGRX is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs SCTL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SCTL has a market cap of 116.13M. Regarding current trading prices, AGRX is priced at $1.51, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AGRX's ROE is +1.04%, compared to SCTL's ROE of -0.15%. Regarding short-term risk, AGRX is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs PROC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PROC has a market cap of 113.95M. Regarding current trading prices, AGRX is priced at $1.51, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, AGRX's ROE is +1.04%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AGRX is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs IRWD Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, IRWD has a market cap of 105.02M. Regarding current trading prices, AGRX is priced at $1.51, while IRWD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas IRWD's P/E ratio is -3.42. In terms of profitability, AGRX's ROE is +1.04%, compared to IRWD's ROE of +0.01%. Regarding short-term risk, AGRX is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs OPTN Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, OPTN has a market cap of 95.40M. Regarding current trading prices, AGRX is priced at $1.51, while OPTN trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas OPTN's P/E ratio is -4.44. In terms of profitability, AGRX's ROE is +1.04%, compared to OPTN's ROE of +0.39%. Regarding short-term risk, AGRX is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ZOM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ZOM has a market cap of 95.35M. Regarding current trading prices, AGRX is priced at $1.51, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AGRX's ROE is +1.04%, compared to ZOM's ROE of -0.22%. Regarding short-term risk, AGRX is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs CRDL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CRDL has a market cap of 91.72M. Regarding current trading prices, AGRX is priced at $1.51, while CRDL trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CRDL's P/E ratio is -3.00. In terms of profitability, AGRX's ROE is +1.04%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, AGRX is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs GRVI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, GRVI has a market cap of 88.91M. Regarding current trading prices, AGRX is priced at $1.51, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AGRX's ROE is +1.04%, compared to GRVI's ROE of -2.44%. Regarding short-term risk, AGRX is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs CPIX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CPIX has a market cap of 74.21M. Regarding current trading prices, AGRX is priced at $1.51, while CPIX trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CPIX's P/E ratio is -20.67. In terms of profitability, AGRX's ROE is +1.04%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, AGRX is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs INCR Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, INCR has a market cap of 71.69M. Regarding current trading prices, AGRX is priced at $1.51, while INCR trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas INCR's P/E ratio is -3.62. In terms of profitability, AGRX's ROE is +1.04%, compared to INCR's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ZYNE Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ZYNE has a market cap of 70.12M. Regarding current trading prices, AGRX is priced at $1.51, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AGRX's ROE is +1.04%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AGRX is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs SSIC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SSIC has a market cap of 66.72M. Regarding current trading prices, AGRX is priced at $1.51, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AGRX's ROE is +1.04%, compared to SSIC's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs VLNS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, VLNS has a market cap of 61.46M. Regarding current trading prices, AGRX is priced at $1.51, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AGRX's ROE is +1.04%, compared to VLNS's ROE of N/A. Regarding short-term risk, AGRX is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs ASRT Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ASRT has a market cap of 58.61M. Regarding current trading prices, AGRX is priced at $1.51, while ASRT trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ASRT's P/E ratio is -2.66. In terms of profitability, AGRX's ROE is +1.04%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, AGRX is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs JUPW Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, JUPW has a market cap of 49.33M. Regarding current trading prices, AGRX is priced at $1.51, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AGRX's ROE is +1.04%, compared to JUPW's ROE of -0.06%. Regarding short-term risk, AGRX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs QLI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, QLI has a market cap of 38.68M. Regarding current trading prices, AGRX is priced at $1.51, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, AGRX's ROE is +1.04%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AGRX is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs SCYX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SCYX has a market cap of 37.07M. Regarding current trading prices, AGRX is priced at $1.51, while SCYX trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SCYX's P/E ratio is -2.16. In terms of profitability, AGRX's ROE is +1.04%, compared to SCYX's ROE of -0.34%. Regarding short-term risk, AGRX is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs RMTI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, RMTI has a market cap of 34.52M. Regarding current trading prices, AGRX is priced at $1.51, while RMTI trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RMTI's P/E ratio is -33.67. In terms of profitability, AGRX's ROE is +1.04%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, AGRX is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs HEXO Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, HEXO has a market cap of 31.24M. Regarding current trading prices, AGRX is priced at $1.51, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AGRX's ROE is +1.04%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AGRX is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs EGRX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, EGRX has a market cap of 25.53M. Regarding current trading prices, AGRX is priced at $1.51, while EGRX trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EGRX's P/E ratio is 2.32. In terms of profitability, AGRX's ROE is +1.04%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, AGRX is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs CYTH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CYTH has a market cap of 23.59M. Regarding current trading prices, AGRX is priced at $1.51, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AGRX's ROE is +1.04%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, AGRX is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs SXTC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SXTC has a market cap of 22.98M. Regarding current trading prices, AGRX is priced at $1.51, while SXTC trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SXTC's P/E ratio is 0.01. In terms of profitability, AGRX's ROE is +1.04%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, AGRX is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs KALA Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, KALA has a market cap of 21.10M. Regarding current trading prices, AGRX is priced at $1.51, while KALA trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas KALA's P/E ratio is -0.32. In terms of profitability, AGRX's ROE is +1.04%, compared to KALA's ROE of -3.89%. Regarding short-term risk, AGRX is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs DRRX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, DRRX has a market cap of 20.12M. Regarding current trading prices, AGRX is priced at $1.51, while DRRX trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DRRX's P/E ratio is -1.08. In terms of profitability, AGRX's ROE is +1.04%, compared to DRRX's ROE of -1.41%. Regarding short-term risk, AGRX is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs IXHL Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, IXHL has a market cap of 19.28M. Regarding current trading prices, AGRX is priced at $1.51, while IXHL trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas IXHL's P/E ratio is -0.49. In terms of profitability, AGRX's ROE is +1.04%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, AGRX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs QNTM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, QNTM has a market cap of 18.56M. Regarding current trading prices, AGRX is priced at $1.51, while QNTM trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas QNTM's P/E ratio is -0.62. In terms of profitability, AGRX's ROE is +1.04%, compared to QNTM's ROE of N/A. Regarding short-term risk, AGRX is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs TXMD Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TXMD has a market cap of 16.90M. Regarding current trading prices, AGRX is priced at $1.51, while TXMD trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TXMD's P/E ratio is -7.30. In terms of profitability, AGRX's ROE is +1.04%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, AGRX is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs FLGC Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, FLGC has a market cap of 15.68M. Regarding current trading prices, AGRX is priced at $1.51, while FLGC trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas FLGC's P/E ratio is -0.53. In terms of profitability, AGRX's ROE is +1.04%, compared to FLGC's ROE of -3.31%. Regarding short-term risk, AGRX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs PRPH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, PRPH has a market cap of 15.41M. Regarding current trading prices, AGRX is priced at $1.51, while PRPH trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PRPH's P/E ratio is -0.15. In terms of profitability, AGRX's ROE is +1.04%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, AGRX is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs ACRX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ACRX has a market cap of 14.58M. Regarding current trading prices, AGRX is priced at $1.51, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AGRX's ROE is +1.04%, compared to ACRX's ROE of -0.40%. Regarding short-term risk, AGRX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs SISI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, SISI has a market cap of 14.41M. Regarding current trading prices, AGRX is priced at $1.51, while SISI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SISI's P/E ratio is -0.01. In terms of profitability, AGRX's ROE is +1.04%, compared to SISI's ROE of -0.84%. Regarding short-term risk, AGRX is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs GELS Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, GELS has a market cap of 13.78M. Regarding current trading prices, AGRX is priced at $1.51, while GELS trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas GELS's P/E ratio is -6.08. In terms of profitability, AGRX's ROE is +1.04%, compared to GELS's ROE of N/A. Regarding short-term risk, AGRX is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs COSM Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, COSM has a market cap of 12.19M. Regarding current trading prices, AGRX is priced at $1.51, while COSM trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas COSM's P/E ratio is -0.34. In terms of profitability, AGRX's ROE is +1.04%, compared to COSM's ROE of -0.51%. Regarding short-term risk, AGRX is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs TLPH Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, TLPH has a market cap of 10.46M. Regarding current trading prices, AGRX is priced at $1.51, while TLPH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TLPH's P/E ratio is -1.02. In terms of profitability, AGRX's ROE is +1.04%, compared to TLPH's ROE of -1.11%. Regarding short-term risk, AGRX is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs AYTU Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, AYTU has a market cap of 8.33M. Regarding current trading prices, AGRX is priced at $1.51, while AYTU trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AYTU's P/E ratio is -0.65. In terms of profitability, AGRX's ROE is +1.04%, compared to AYTU's ROE of -0.18%. Regarding short-term risk, AGRX is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs NLTX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, NLTX has a market cap of 8.20M. Regarding current trading prices, AGRX is priced at $1.51, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AGRX's ROE is +1.04%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, AGRX is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs LCI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, LCI has a market cap of 7.38M. Regarding current trading prices, AGRX is priced at $1.51, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, AGRX's ROE is +1.04%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AGRX is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs BGXX Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BGXX has a market cap of 7.26M. Regarding current trading prices, AGRX is priced at $1.51, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BGXX's P/E ratio is -0.76. In terms of profitability, AGRX's ROE is +1.04%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, AGRX is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs ADMP Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, ADMP has a market cap of 7.25M. Regarding current trading prices, AGRX is priced at $1.51, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AGRX's ROE is +1.04%, compared to ADMP's ROE of +0.00%. Regarding short-term risk, AGRX is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.
AGRX vs CPHI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, CPHI has a market cap of 7.24M. Regarding current trading prices, AGRX is priced at $1.51, while CPHI trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CPHI's P/E ratio is -0.82. In terms of profitability, AGRX's ROE is +1.04%, compared to CPHI's ROE of -0.63%. Regarding short-term risk, AGRX is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.
AGRX vs BFRI Comparison
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.43M. In comparison, BFRI has a market cap of 6.60M. Regarding current trading prices, AGRX is priced at $1.51, while BFRI trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BFRI's P/E ratio is -0.22. In terms of profitability, AGRX's ROE is +1.04%, compared to BFRI's ROE of -4.60%. Regarding short-term risk, AGRX is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.